BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05335122 (OTX-TIC in Open Angle Glaucoma Ocular Hypertension): BVCT ex-ante prediction vs. reported outcome

On 16 Feb 2024, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 6 Apr 2024 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient (non-inferior).

Clinical Trial

NCTID
NCT05335122
Drug Name
OTX-TIC (Travoprost)
Drug MoA
travoprost intracameral implant
Drug Modality
medical device
Drug Class
Best-In-Class
Therapeutic Area
Eye Diseases
Indication
Open Angle Glaucoma Ocular Hypertension
Human Patients
105
Sponsor
Ocular Therapeutix
Phase
Phase 2

Prediction of , index 1474

Prospective Prediction
Prediction Index
1474
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit non-inferior to durysta)
Technical Prediction
SUCCESS (statistically significant clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
50 days in advance
Readout Data Interpretation
24-30% IOP reduction at 6 months (vs 23-33% for durtsta or timolol) with 81.3% eyes requiring no additional treatment at 6 month (vs 81.8% for durysta and 90% for timolol).
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient (non-inferior)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Phase
Phase 2
Status
Completed
Enrollment
83
Lead sponsor
Ocular Therapeutix, Inc.
Conditions
Open Angle Glaucoma; Ocular Hypertension
Interventions
DRUG: OTX-TIC low dose Travoprost Intracameral Implant; DRUG: OTX-TIC high dose Travoprost Intracameral Implant; DRUG: Durysta, Bimatoprost Intracameral Implant 10 µg
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2022-03-16
Primary completion
2024-01-24
Completion
2025-01-24
Results first posted
2026-09-03
Primary outcomes
  • IOP Changes From Baseline in the Study Eye (Baseline (8AM, 10 AM, 4 PM) to Week 2 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 6 (8 AM, 10 AM, 4 PM) Baseline (8AM, 10 AM, 4 PM) to Week 12 (8 AM, 10 AM, 4 PM))

NCT05335122 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials